Clozapine: past, present and future DOI
Christoph U. Correll

World Psychiatry, Journal Year: 2025, Volume and Issue: 24(2), P. 153 - 154

Published: May 15, 2025

Letter to the editor concerning: “Efficacy, tolerability, and safety of xanomeline-trospium chloride for schizophrenia: A systematic review and meta-analysis” DOI
Chengji J. Zhou, Miao Jiang, Haiyang Chen

et al.

European Neuropsychopharmacology, Journal Year: 2025, Volume and Issue: 94, P. 16 - 16

Published: Feb. 16, 2025

Language: Английский

Citations

1
Response to the Letter to the Editor “Reflections on a study of electroconvulsive therapy for clozapine-refractory schizophrenia” (Jolly et al. Schizophrenia Research, 267 (2024) 32-33) DOI
Hélio Elkis, Christoph U. Correll, Débora Luciana Melzer-Ribeiro

et al.

Schizophrenia Research, Journal Year: 2025, Volume and Issue: 276, P. 15 - 16

Published: Jan. 18, 2025

Language: Английский

Citations

0
Differential effects of Xanomeline-trospium chloride on positive and negative symptoms in Schizophrenia: The role of dose DOI
Tai‐Ho Hung, Yi‐Hsiang Hsu, Yang‐Chieh Brian Chen

et al.

European Neuropsychopharmacology, Journal Year: 2025, Volume and Issue: 93, P. 22 - 23

Published: Jan. 31, 2025

Language: Английский

Citations

0
Novel pharmaceutical treatment approaches for schizophrenia: a systematic literature review DOI
Anan S. Jarab, Walid Al‐Qerem,

Adam Khdour

et al.

European Journal of Clinical Pharmacology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 14, 2025

Language: Английский

Citations

0
On the potential of xanomeline-trospium chloride for schizophrenia and beyond DOI
Nicholas Fabiano, Stanley Wong, Carl Zhou

et al.

European Neuropsychopharmacology, Journal Year: 2025, Volume and Issue: 94, P. 17 - 18

Published: Feb. 16, 2025

Language: Английский

Citations

0
A New Era of Muscarinic Acetylcholine Receptor Modulators in Neurological Diseases, Cancer and Drug Abuse DOI Creative Commons

Helena Tsimpili,

Grigoris Zoidis

Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(3), P. 369 - 369

Published: March 5, 2025

The cholinergic pathways in the central nervous system (CNS) play a pivotal role different cognitive functions of brain, such as memory and learning. This review takes dive into pharmacological side this important part CNS function, taking consideration muscarinic receptors cholinesterase enzymes. Targeting specific subtype five primary receptor subtypes (M1-M5) through agonism or antagonism may benefit patients; thus, there is great pharmaceutical research interest. Inhibition AChE BChE, orthosteric allosteric, partial M1 mAChR are correlated with Alzheimer’s disease (AD) symptoms improvement. Agonism on subunits lessen schizophrenia (especially positive allosteric modulation M4 mAChR). Selective promising treatment for Parkinson’s dystonia, adverse effects limited compared to inhibition all mAChR. Additionally, selective M5 plays drug independence behavior. M3 overexpression associated malignancies, M3R antagonists seem have therapeutic potential cancer, while M1R M2R leads reduction neoangiogenesis. Depending type promote cancer cell proliferation (as does) protection against further tumor development (M1R agonism). Thus, an intense need discover new potent compounds action subtypes. Chemical structures, chemical modification function groups aiming at enhancement, effects, optimization Drug Metabolism Pharmacokinetics (DMPK) will be discussed, well protein–ligand docking.

Language: Английский

Citations

0
Muscarinic acetylcholine receptor agonists in bipolar disorder DOI

Meritxell González‐Campos,

Eduard Vieta

European Neuropsychopharmacology, Journal Year: 2025, Volume and Issue: 95, P. 4 - 5

Published: March 8, 2025

Language: Английский

Citations

0
The Importance of Antipsychotic Treatment in Severe Mental Disorders DOI Creative Commons
Pasquale Paribello, Marco Solmi, Mirko Manchia

et al.

Psychiatry International, Journal Year: 2025, Volume and Issue: 6(2), P. 35 - 35

Published: March 24, 2025

Antipsychotics are the cornerstone of clinical management severe psychiatric disorders [...]

Language: Английский

Citations

0
Does KarXT (xanomeline-trospium) represent a novel approach to schizophrenia management? A GRADE-assessed systematic review and meta-analysis of randomized controlled clinical trials DOI Creative Commons

Hazem Mohammed,

M. Gomaa,

Y. Khalifa

et al.

BMC Psychiatry, Journal Year: 2025, Volume and Issue: 25(1)

Published: March 31, 2025

Abstract Background Schizophrenia is a complex psychiatric disorder characterized by positive, negative, and cognitive symptoms. KarXT, novel combination of xanomeline trospium, offers potential therapeutic benefits for schizophrenia treatment targeting muscarinic receptors avoiding dopamine receptor blockade. We conducted systematic review meta-analysis to evaluate the efficacy safety KarXT. Methods PubMed, Scopus, Web Science, Cochrane databases were systematically searched relevant randomized controlled trials (RCTs) up October 2024. Studies involving adult patients with treated KarXT included. Furthermore, Grading Recommendations, Assessment, Development, Evaluation (GRADE) framework was used assess evidence quality, risk bias evaluated using Risk Bias 2.0 tool. Results Four studies 690 participants significantly reduced Positive Negative Syndrome Scale (PANSS) total scores compared placebo (mean difference (MD): -13.77, 95% confidence interval (CI) [-22.33 -5.20], P-value = 0.002), significant improvements in positive negative subscale scores. It increased incidence achieving ≥ 30% PANSS score reduction (risk ratio: 2.15, CI [1.64 2.84], P < 0.00001). Moreover, demonstrated favorable profile, side effects such as nausea constipation being mild transient. Notably, it not associated weight gain or extrapyramidal symptoms, which are common traditional antipsychotics. Conclusions KarXT’s distinct mechanism tolerability highlight its address unmet needs treatment. Future should explore long-term efficacy, delayed adverse effects, comparative effectiveness against existing therapies. Clinical trial number Not applicable.

Language: Английский

Citations

0
Is muscarinic receptor agonist effective and tolerant for schizophrenia? DOI Creative Commons
Xiaonan Guo,

Rongshan Deng,

Jianbo Lai

et al.

BMC Psychiatry, Journal Year: 2025, Volume and Issue: 25(1)

Published: April 2, 2025

Several randomized clinical trials (RCTs) have recently examined the efficacy and tolerability of muscarinic receptor agonists in schizophrenia. However, whether therapeutics targeting receptors improve symptom management reduce side effects remains systemically unexplored. Embase, PubMed, Web Science were searched from inception until Jan 9, 2025. Altogether, safety outcomes four RCTs (397 individuals group, 374 placebo control group) meta-analyzed. To compare scores positive negative syndrome scale (PANSS), response rate, discontinuation adverse events with vs. patients schizophrenia, changes pooled as mean difference (MD) for continuous risk ratio (RR) categorical outcomes. It revealed that superior to terms decrease total PANSS score (MD, - 9.92; 95% CI, -12.46 -7.37; I2 = 0%), subscore 3.21; -4.02 -2.40; -1.79; -2.47 -1.11; 48%). According study-defined RR was 2.08 (95% 1.59 2.72; 0%). No significance found rate. Muscarinic associated a higher nausea (RR 4.61, 2.65 8.02; 3%), particular, xanomeline-trospium risks dyspepsia, vomiting, constipation. The findings highlighted an advantage tolerated event profiles

Language: Английский

Citations

0